World · Malaysia Bureau
US FDA mandates GLP-1 drugs carry warning of rare eye condition risk
The US Food and Drug Administration has required manufacturers of GLP-1 diabetes and weight-loss medications to add warnings about a potentially increased risk of a rare but serious eye condition that could cause permanent vision loss.
LSN Malaysia ·
The regulatory move represents a significant step in ensuring patient safety as the class of medications, which includes popular drugs like semaglutide and tirzepatide, continues to gain widespread use globally. The FDA's decision stems from emerging evidence linking GLP-1 receptor agonists to non-arteritic anterior ischaemic optic neuropathy, a condition affecting blood flow to the optic nerve that can result in sudden vision loss.
Drugmakers must now update their product labelling to reflect the potential risk and inform healthcare practitioners and patients of the warning. The requirement applies across all GLP-1 medications approved for treating type 2 diabetes and obesity, though regulators have noted that such eye complications remain uncommon among users of these drugs.
The advisory does not signal a recommendation to cease use of the medications, which have demonstrated significant benefits in managing blood sugar levels and weight reduction. Instead, the warning aims to support informed decision-making between patients and their doctors, particularly for those with existing risk factors or eye conditions.
Healthcare providers in the region will likely receive updated prescribing information in coming weeks, allowing them to counsel patients appropriately. The move underscores the importance of ongoing pharmacovigilance as these medications see expanding use across Asia-Pacific markets.